Edgewise Therapeutics

Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates across key profitability metrics, with a GAAP EPS of -$0.53 vs. -$0.47 expected, primarily driven by higher-than-anticipated R&D and G&A spending. While revenue remained at zero as expected for a clinical-stage biotech, total operating expenses of $61.9M significantly exceeded the estimated EBIT loss of $55.2M. However, the post-quarter sale of the muscular dystrophy business to Servier for $1.55B upfront drastically transforms the balance sheet, providing a pro forma cash position of over $2B to fund the advancing cardiovascular pipeline.